来源：市场资讯 根据收购协议，辉瑞将以每股47.50美元的现金价格收购Metsera，这一价格较这家总部位于纽约的公司 上一交易日收盘价溢价约43%。 此外，若特定业绩里程碑达成，Metsera股东还可额外获得每股22.50美元的款项。消息公布后，Metsera 股价飙升逾60%，至53.8美元，而辉瑞股价上涨约2%。 该交易预计将于2025年第四季度完成。 （来源：医趋势） 9月22日，辉瑞宣布将收购创新药企Metsera，交易总价最高可达73亿美元（含后续款项）。此举旨在帮 助辉瑞在快速增长的肥胖治疗市场中稳固地位。 据市场分析，预计到2030年初，全球肥胖药物市场规模将达到1500亿美元。目前，该市场增长主要受诺 和诺德（Novo Nordisk）、礼来（Eli Lilly）等公司的GLP-1类疗法快速普及推动。当前，各大药企正竞 相研发下一代肥胖治疗药物，其中就包括能帮助患者在减脂的同时维持肌肉量的激素类药物。 辉瑞首席科学官Chris Boshoff表示："一款耐受性良好且可每月给药的药物将具备巨大优势——这不仅 体现在患者体重的维持上，还能提升用药便利性与患者依从性。" 此前，辉瑞自研的减重药物d ...

格隆汇9月24日｜杰富瑞将辉瑞的目标价从33美元上调至34美元。 ...

Making a major move in the obesity drug market, Pfizer (PFE)  announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR)  by the end of the year for $4.9 billion or $47.50 a share.The deal has a potential value of up to $7.3 billion when including milestone-based payments of up to $22.50 per share, which would bring the total acquisition stock price for MTSR up to $70.In the wake of the news, Metsera stock has surged +60% to over $50, with the price performance of Pfizer shares being vir ...

Pfizer Inc. (NYSE:PFE) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In. The company raises its Adjusted Diluted EPS guidance and raises its total savings goal amid a revenue increase in Q2 2025. Pfizer Raises EPS Guidance and Expands Cost-Cutting Plan While Boosting Dividend Appeal Pfizer Inc. (NYSE:PFE)’s second-quarter results were reported on August 5, 2025, where it highlighted a year-over-year increase in revenue of 10%, reaching $14.7 billion. The revenue growth was partly contribut ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Pfizer Inc. is one of them. Pfizer Inc. (NYSE:PFE), a global biopharmaceutical leader, continues to make strides in vaccines and oncology, reinforcing its position in the pharma sector. In September 2025, PFE and BioNTech reported positive Phase 3 data for the LP.8.1-adapted COMIRNATY 2025-2026 COVID-19 vaccine. The updated formulation produced at least a four-fold increase in neutralizing antibodies ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Metsera, Inc. (NASDAQ: MTSR) related to its sale to Pfizer Inc. Under the terms of the pr ...

We recently published 10 Stocks Stealing Wall Street’s Spotlight. Metsera Inc. (NASDAQ:MTSR) is one of the top performers on Monday. Shares of Metsera Inc. (NASDAQ:MTSR) jumped to a new all-time high on Monday, as investors gobbled up shares following news that it was set to be acquired by Pfizer Inc. (NYSE: PFE) for a potential transaction value of more than $7 billion. During the session, Metsera Inc. (NASDAQ:MTSR) soared to its highest price of $54.46 before trimming gains to close the day just up by ...

Key Takeaways Pfizer will buy Metsera for $47.50 per share, plus up to $22.50 CVR on clinical milestones.Metsera adds four obesity drug programs, led by GLP-1 agonist MET-097i in phase II studies.The acquisition marks Pfizer's return to obesity after halting danuglipron earlier this year.Pfizer (PFE) announced a definitive agreement to acquire obesity drug developer, Metsera (MTSR) , to re-enter the lucrative obesity space after it scrapped the development of danuglipron, a weight-loss pill, earlier this ye ...

每经记者｜陈星 每经编辑｜张海妮 减重药物赛道的较量越来越激烈。 首先是在药物数据上"你来我往"——今年8月，礼来公布ATTAIN-1研究数据，在第72周，礼来在研口服 小分子GLP-1 RA（胰高血糖素样肽-1受体激动剂）药物Orforglipron最高剂量组平均减重12.4kg（降幅 12.4%）。 近期，诺和诺德方面公布了发表在《新英格兰医学杂志》上的口服司美格鲁肽片Ⅲ期试验OASIS 4的结 果。试验结果显示，在64周时，在所有患者依从治疗的情况下，口服司美格鲁肽片25mg组患者实现了 16.6%的平均体重降幅。 其次，MNC（跨国制药企业）也在不断"扫货"GLP-1，随着近日辉瑞宣布以73亿美元收购Metsera，这 一市场的BD（商务拓展）预期和商业化预期都正在被逐步透支。 礼来、诺和诺德"你来我往" 礼来、诺和诺德在GLP-1赛道的竞争愈演愈烈。 礼来公布Orforglipron的Ⅲ期临床研究"ACHIEVE-3"的顶线结果，该结果优于口服司美格鲁肽的结果 后，诺和诺德公布了Ⅲ期试验OASIS 4的结果。在此项为期64周的试验中，口服司美格鲁肽片25mg联合 生活方式干预，在307名肥胖或超重且 ...

U.S. stock futures presented a mixed picture in premarket trading on Tuesday, September 23, 2025, as investors digested a flurry of corporate news and awaited key economic signals, most notably a speech from Federal Reserve Chair Jerome Powell. This follows a robust Monday session where major indices notched their third consecutive day of record closing highs, largely propelled by optimism surrounding artificial intelligence and expectations of further Federal Reserve rate cuts.Premarket Trading Activity an ...